Published in:
01-01-2015 | Editorial
Mortality is the only relevant outcome in ARDS: no
Author:
John P. Kress
Published in:
Intensive Care Medicine
|
Issue 1/2015
Login to get access
Excerpt
The design of a prospective clinical trial requires careful consideration of outcomes to be targeted. Traditionally, mortality has been the most relevant and coveted outcome for prospective clinical trials in acute respiratory distress syndrome (ARDS). However, recently the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), ARDS Network has developed the NHLBI-funded Prevention and Treatment of Acute Lung Injury (PETAL) Network. This shift reflects the sentiment that many experts have regarding the future of ARDS outcomes research. Specifically, the notion that mortality should be the preferred outcome for ARDS trials is no longer a valid argument. This contribution to the editorial debate presents reasons why other outcomes besides mortality are relevant to the future design of ARDS trials. …